Abstract
We investigated a new oral penem, SY5555, for its clinical efficacy and safety. SY5555 was orally administered to 25 patients with endometritis, uterine adnexitis, bartholinitis (abscess), mastitis, cervicitis and vulvar abscess. Clinical evaluation was possible in 18 patients (administration at a dose of 100-200mg, 2 or 3 times a day for 3-8 days). The clinical results were evaluated as good in 14 and poor in 4. The efficacy rate was 77.8%. Bacteriologically, of seven organisms isolated from 6 patients, six were eradicated and one was unknown. Clinical safety was evaluated in 23 patients. As to adverse reactions, eruption was observed in one, and we noted eruption, diarrhea and nausea in another. In laboratory tests, an elevation of GPT was observed in one patient.
